scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients

scPharmaceuticals Inc SCPH announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure.
Patients were treated with the Company's investigational Furoscix, post-discharge from the emergency department, compared to a historical comparator group treated with intravenous furosemide in the inpatient hospital setting.
Due to a statistically significant reduction observed in 30-day heart failure-related costs in patients who received Furoscix in the interim analysis, enrollment was stopped early.
The mean difference in heart failure-related costs between the two groups was $17,753 per study subject, favoring the Furoscix group.
Subjects who received Furoscix did not require an initial heart failure hospitalization, and all but one remained out of the hospital for heart failure for the subsequent 30-day period.
In the comparator group, 100% of the patients were initially hospitalized, and 10.6% had a heart failure-related readmission.
The most common adverse events with Furoscix were infusion site pain, bruising, and dizziness, with no serious adverse events observed.
scPharmaceuticals' management will host a conference call and live webcast today at 8:30 am ET.
Price Action: SCPH shares are up 4.56% at $6.88 premarket on the last check Wednesday.